Holen Sie sich die Stockscreener-App
4.83
27.15%
-1.80
Vorhandelsmarkt:
5.09
0.26
+5.38%
Schlusskurs vom Vortag:
$6.63
Offen:
$5.67
24-Stunden-Volumen:
585.88K
Relative Volume:
3.07
Marktkapitalisierung:
$10.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.77M
KGV:
-0.3158
EPS:
-15.2954
Netto-Cashflow:
$-24.23M
1W Leistung:
-36.36%
1M Leistung:
-59.53%
6M Leistung:
-70.82%
1J Leistung:
-91.64%
1-Tages-Spanne:
$4.75
$5.8815
1-Wochen-Bereich:
$4.75
$7.98
52-Wochen-Spanne:
$4.75
$91.25
Moleculin Biotech Inc Stock (MBRX) Company Profile
Firmenname
Moleculin Biotech Inc
Sektor
Branche
Telefon
713-300-5160
Adresse
5300 MEMORIAL DRIVE, HOUSTON, TX
Vergleichen Sie MBRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
4.83 | 13.72M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-09 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-12 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten
Moleculin Biotech Enters Inducement Offer Agreements - TipRanks
Moleculin Biotech stock falls after warrant exercise agreement By Investing.com - Investing.com UK
Moleculin Biotech stock falls after warrant exercise agreement - Investing.com India
Moleculin Biotech raises $6.5 million through warrant exercise By Investing.com - Investing.com Australia
Moleculin Biotech, Inc. Announces Immediate Exercise of Warrants for Gross Proceeds of Approximately $6.5 Million - Quiver Quantitative
Moleculin Biotech (Nasdaq: MBRX) enters warrant exercise deals for approx $6.5M - Stock Titan
Moleculin Biotech (MBRX) Stock: Faces Market Drop Despite Positive MIRACLE Trial Enrollment Progress - parameter.io
Moleculin shares rise 6% as enrollment nears key milestone in AML trial - MSN
Moleculin Biotech (MBRX) Approaches Key Enrollment Milestone in Leukemia Study - GuruFocus
Moleculin Biotech Updates on MIRACLE Study Progress - TipRanks
Moleculin stock rises as AML trial enrollment reaches 78% By Investing.com - Investing.com UK
Moleculin Biotech, Inc. Updates on MIRACLE Phase 2B/3 AML Trial Progress - TradingView
Moleculin reports 78% enrollment in AML treatment trial By Investing.com - Investing.com Canada
Moleculin Announces Completion of Treatment for the 45 - GlobeNewswire
Moleculin enters research agreement for brain cancer treatment By Investing.com - Investing.com South Africa
Moleculin Biotech Partners with CIC biomaGUNE for Research - TipRanks
Moleculin Biotech (MBRX) Partners with CIC biomaGUNE for Brain C - GuruFocus
Moleculin Announces New Annamycin Collaboration in Brain Tumors - The Manila Times
Moleculin Biotech, Inc. Partners with CIC biomaGUNE for Preclinical Research on Annamycin as a Treatment for Glioblastoma Multiforme - Quiver Quantitative
Moleculin announces new Annamycin collaboration in brain tumors - marketscreener.com
Moleculin (Nasdaq: MBRX) joins CIC biomaGUNE to study Annamycin in GBM models - Stock Titan
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy - MSN
Moleculin Biotech (MBRX) Price Target Increased by 2,399.99% to 170.00 - Nasdaq
Net debt of Moleculin Biotech, Inc. – FWB:MOL0 - TradingView
After tax other income/expense of Moleculin Biotech, Inc. – MUN:MOL0 - TradingView
Basic earnings per share (basic EPS) of Moleculin Biotech, Inc. – LS:A41SET - TradingView
Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Geopolitics Watch: Why Moleculin Biotech Inc. stock remains a top recommendationJuly 2025 Reactions & Fast Momentum Entry Tips - BỘ NỘI VỤ
Moleculin Biotech, Inc.: Revenue and Earnings Analysts Forecasts Revisions | MOL0 | US60855D4088 - marketscreener.com
Moleculin Biotech, Inc.: Financial Data Forecasts Estimates and Expectations | MOL0 | US60855D4088 - marketscreener.com
Moleculin Biotech, Inc.: Dividend historical data and projections - marketscreener.com
Moleculin Biotech, Inc.: Target Price Consensus and Analysts Recommendations | MOL0 | US60855D4088 - marketscreener.com
How supply shortages influence Moleculin Biotech Inc. (MOL) stockPortfolio Profit Report & Precise Swing Trade Alerts - Newser
Moleculin Biotech Inc (FRA:MOL0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Moleculin Biotech Inc (FRA:MOL0) Stock Earnings Transcripts - GuruFocus
Why Moleculin Biotech Inc. stock attracts global investors2025 Institutional Moves & Risk Controlled Swing Trade Alerts - Newser
Enterprise value to EBITDA ratio of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Price to cash flow ratio of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Why analysts maintain buy rating on Moleculin Biotech Inc. (MOL) stockGDP Growth & Reliable Momentum Entry Alerts - Newser
Number of employees of Moleculin Biotech, Inc. – MUN:MOL0 - TradingView
Moleculin Biotech, Inc. Financial Statements – FWB:MOL0 - TradingView
Net debt of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Non-controlling/minority interest of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Diluted net income available to common stockholders of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Operating income of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Gross profit of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Moleculin Biotech, Inc. Statistics – BER:MOL0 - TradingView
Non-operating income (total) of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Taxes of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Diluted earnings per share (diluted EPS) of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Preferred dividends of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Finanzdaten der Moleculin Biotech Inc-Aktie (MBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):